(CAPR) Capricor Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.713m USD | Total Return: 165.8% in 12m
Avg Turnover: 29.1M
Qual. Beats: -2
Qual. Beats: 0
Warnings
Share dilution 25.9% YoY
Interest Coverage Ratio -39.4 is critical
Altman Z'' -9.21 < 1.0 - financial distress zone
Tailwinds
Leader
Capricor Therapeutics Inc (NASDAQ: CAPR) is a San Diego-based biotechnology firm focused on developing cell and exosome-based therapies for rare diseases. The company’s primary focus is Deramiocel, an allogeneic cardiosphere-derived cell therapy currently in Phase 3 clinical trials for Duchenne Muscular Dystrophy (DMD). Their pipeline also includes the StealthX Exosome Platform, which is being utilized to engineer vaccines and targeted therapeutics for various indications, including SARS-CoV-2.
The company operates within the high-risk, high-reward biotechnology sector, where success is heavily dependent on the clinical trial outcomes and regulatory approval processes of the FDA. Capricor utilizes a collaborative business model, maintaining strategic licensing agreements with academic institutions like Johns Hopkins University and Cedars-Sinai Medical Center to secure intellectual property and technical know-how. This model allows clinical-stage firms to leverage foundational research while focusing internal resources on late-stage development and commercialization pathways.
Investors should consult ValueRay to better understand the risk profile associated with clinical-stage biotech assets. The firm’s future revenue potential remains contingent on the transition of its lead candidates from experimental phases to commercial availability in the United States market.
- Deramiocel Phase 3 clinical trial results determine short-term stock valuation and FDA approval path
- Nippon Shinyaku partnership expansion provides non-dilutive capital and commercialization infrastructure for DMD
- Regulatory approval timelines for Deramiocel drive long-term revenue projections and market entry
- StealthX exosome platform development progress impacts future pipeline diversification and partnership potential
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -4.25 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.28 > 3% & CFO -92.6m > Net Income -114.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.4m) vs 12m ago 25.85% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 11.29%; Δ -11.29% > 0%) |
| Interest Coverage Ratio: -39.38 > 6 (EBITDA TTM -117.9m / Interest Expense TTM 3.05m) |
| A: 0.76 (Total Current Assets 283.1m - Total Current Liabilities 33.6m) / Total Assets 326.3m |
| B: -1.04 (Retained Earnings -338.8m / Total Assets 326.3m) |
| C: -0.50 (EBIT TTM -119.9m / Avg Total Assets 240.0m) |
| D: -7.13 (Book Value of Equity -339.0m / Total Liabilities 47.6m) |
| Altman-Z'' = -9.21 = D |
As of May 24, 2026, the stock is trading at USD 29.58 with a total of 861,897 shares traded.
Over the past week, the price has changed by +0.28%,
over one month by -17.51%,
over three months by +3.59% and
over the past year by +165.84%.
Capricor Therapeutics has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy CAPR.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 54.1 | 82.9% |
P/S = 124.4331
P/B = 6.1423
P/EG = 0.3831
Revenue TTM = 0.0 USD
EBIT TTM = -119.9m USD
EBITDA TTM = -117.9m USD
Long Term Debt = 13.9m USD (estimated: total debt 21.1m - short term 7.18m)
Short Term Debt = 7.18m USD (from shortTermDebt, last quarter)
Debt = 35.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 14.8m
Net Debt = -242.7m USD (calculated: Debt 35.9m - CCE 278.6m)
Enterprise Value = 1.47b USD (1.71b + Debt 35.9m - CCE 278.6m)
Interest Coverage Ratio = -39.38 (Ebit TTM -119.9m / Interest Expense TTM 3.05m)
EV/FCF = -12.90x (Enterprise Value 1.47b / FCF TTM -114.0m)
FCF Yield = -7.75% (FCF TTM -114.0m / Enterprise Value 1.47b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 4.51 (Enterprise Value 1.47b / Total Assets 326.3m)
Interest Expense / Debt = 8.48% (Interest Expense 3.05m / Debt 35.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -94.7m (EBIT -119.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.42 (Total Current Assets 283.1m / Total Current Liabilities 33.6m)
Debt / Equity = 0.13 (Debt 35.9m / totalStockholderEquity, last quarter 278.7m)
Debt / EBITDA = 2.06 (negative EBITDA) (Net Debt -242.7m / EBITDA -117.9m)
Debt / FCF = 2.13 (negative FCF - burning cash) (Net Debt -242.7m / FCF TTM -114.0m)
Total Stockholder Equity = 193.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.74% (Net Income -114.6m / Total Assets 326.3m)
RoE = -21.53% (Net Income TTM -114.6m / Total Stockholder Equity 532.2m)
RoCE = -21.96% (EBIT -119.9m / Capital Employed (Equity 532.2m + L.T.Debt 13.9m))
RoIC = -446.6% (out of range, set to none) (NOPAT -94.7m / Invested Capital 21.2m)
WACC = 12.24% (E(1.71b)/V(1.75b) * Re(12.36%) + D(35.9m)/V(1.75b) * Rd(8.48%) * (1-Tc(0.21)))
Discount Rate = 12.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 40.37%
[DCF] Fair Price = unknown (Cash Flow -114.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.32 | # QB: -2
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.59 | Chg30d=-13.29% | Revisions=-33% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.47 | Chg30d=N/A | Revisions=-56% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.39 | Chg30d=-559.43% | Revisions=-20% | GrowthEPS=+83.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.76 | Chg30d=-101.00% | Revisions=-33% | GrowthEPS=-98.4% | GrowthRev=+0.2%
[Analyst] Revisions Ratio: -56%